- High BMI was associated with better survival in patients with NSCLC treated with second- or later-line immune checkpoint inhibitors (ICIs).
Why this matters
- Prior studies suggested BMI was associated with the efficacy of ICIs in solid tumors such as melanomas, but its link to ICI efficacy in patients with NSCLC was unclear.
- 84 patients with NSCLC with programmed death-ligand 1 (PD-L1) expression ≥50% were treated with pembrolizumab as first-line therapy (cohort 1), and 429 patients with NSCLC who received nivolumab/pembrolizumab/atezolizumab as second- or later-line treatment (cohort 2).
- Funding: None disclosed.
- BMI was not associated with survival in cohort 1.
- Patients in cohort 2 with high BMI had significantly better PFS (3.7 vs 2.8 months; P=.036) and OS (15.4 vs 13.5 months; P=.021) than those with low BMI.
- Patients with high BMI and PD-L1 ≥50% had significantly better PFS (17.0 vs 3.5 months; P=.007) and OS (not reached vs 16.1 months; P=.031) than patients with low BMI and/or PD-L1
- Patients with PD-L1 ≥50% had significantly better PFS (9.4 vs 2.8 months; P<.001 and os vs months p=".013)" than those with pd-l1>
- Retrospective study.